Edition:
United Kingdom

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

26.41USD
14 Dec 2018
Change (% chg)

$-0.68 (-2.51%)
Prev Close
$27.09
Open
$26.80
Day's High
$27.00
Day's Low
$26.09
Volume
84,709
Avg. Vol
71,457
52-wk High
$35.48
52-wk Low
$21.27

Select another date:

Fri, Nov 9 2018

Mylan and Theravance's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

UPDATE 2-Mylan and Theravance's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Mylan and Theravance Biopharma's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Select another date: